四种血清生物标志物对小腹主动脉瘤患者主要不良事件的预测价值
本研究在471例直径30-54 mm的小腹主动脉瘤患者中检测C反应蛋白、纤维蛋白原、中性粒细胞-淋巴细胞比值和同型半胱氨酸,随访中位2.4年,102例(21.7%)发生主要不良心血管事件。校正其他危险因素后,仅C反应蛋白与主要不良心血管事件风险独立相关(HR 1.19,95%CI 1.05-1.35),并显著改善风险分类。
要点
- 小腹主动脉瘤患者中,C反应蛋白升高与主要不良心血管事件风险独立相关(HR 1.19,95%CI 1.05-1.35)。
- 纤维蛋白原、中性粒细胞-淋巴细胞比值和同型半胱氨酸均与主要不良心血管事件风险无关。
- C反应蛋白较临床危险因素单独可显著改善主要不良心血管事件的风险分类。
核心结论
- C反应蛋白可辅助小腹主动脉瘤患者主要不良心血管事件的风险分类。
研究设计与样本
- 研究纳入471例直径30-54 mm的腹主动脉瘤参与者,检测血清C反应蛋白、纤维蛋白原、中性粒细胞-淋巴细胞比值和同型半胱氨酸。
- 主要结局为主要不良心血管事件,定义为心肌梗死、卒中或心血管死亡的首次发生。
- 采用Kaplan-Meier和Cox比例风险分析评估生物标志物与事件的关联,采用净重分类指数评估生物标志物加入临床危险因素后的风险分类改善。
主要发现
- 参与者随访中位2.4年(四分位距0.8-5.4年),102例(21.7%)发生主要不良心血管事件。
- 2.5年时,C反应蛋白>3.0 mg/L者的主要不良心血管事件发生率为13.2%,C反应蛋白≤3.0 mg/L者为10.1%(P = .047)。
- 校正其他危险因素后,较高的C反应蛋白与显著升高的主要不良心血管事件风险相关(HR 1.19,95%CI 1.05-1.35)。
- 其他生物标志物均与主要不良心血管事件风险无关。
- 根据净重分类指数,C反应蛋白较临床危险因素单独显著改善了主要不良心血管事件的风险分类。
临床怎么用
- 作者认为,C反应蛋白可辅助小腹主动脉瘤患者主要不良心血管事件的风险分类。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The primary aim of this study was to test which of a group of four inflammation and thrombosis biomarkers were independently predictive of major adverse cardiovascular events (MACE) in patients with small abdominal aortic aneurysm (AAA). METHODS: A total of 471 participants with a 30- to 54-mm AAA had serum C-reactive protein (CRP), fibrinogen, neutrophil-lymphocyte ratio (NLR), and homocysteine measured. The primary outcome was MACE, which was defined as the first occurrence of myocardial infarction, stroke, or cardiovascular death. The association of biomarkers with events was assessed using Kaplan-Meier and Cox proportional hazard analyses. The net improvement in risk of event categorization with addition of a biomarker to clinical risk factors alone was assessed using net reclassification index. RESULTS: Participants were followed for a median of 2.4 years (interquartile range, 0.8-5.4 years), and 102 (21.7%) had a MACE. The incidence of MACE was 13.2% in participants with CRP >3.0 mg/L, compared with 10.1% in those with CRP ≤3.0 mg/L at 2.5 years (P = .047). After adjusting for other risk factors, higher CRP was associated with a significantly higher risk of MACE (hazard ratio, 1.19; 95% confidence interval, 1.05-1.35). None of the other biomarkers were associated with the risk of MACE. According to the net reclassification index, CRP significantly improved the risk classification of MACE compared with clinical risk factors alone. CONCLUSIONS: CRP can assist in classification of risk of MACE for patients with small AAA.
引用
- Golledge J, Velu R, Quigley F, et al. The predictive value of four serum biomarkers for major adverse events in patients with small abdominal aortic aneurysm. J Vasc Surg. 2022. PMID: 36526087. doi:10.1016/j.jvs.2022.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。